Telus Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher CBIO Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Progresses Neurocrine Biosciences NBIX Q1 2026 Earnings EPS Smashes Estimates Stock Edges Higher Telomir Pharmaceuticals Q4 2025 Earnings Wider Than Expected Loss Highlights ClinicalStage Challenges Ovid Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Supports Biotechs Cash Discipline RLAY Q1 2026 Earnings EPS Misses Consensus PreRevenue Biotech Maintains RD Focus